Bottom line
VHT vs LOGSX: the short answer
VHT (Vanguard Health Care Index Fund) and LOGSX (Live Oak Health Sciences Fund) are quite different portfolios: only about 32% of their top holdings (by weight) are shared.
But VHT is far broader, holding 407 positions to 28 for LOGSX, so beyond the top names it adds exposure LOGSX doesn't have.
VHT is cheaper at 0.09% vs 1.04% — a difference of $95 a year per $10,000 invested.
Over five years, LOGSX returned +8.1% a year vs +7.2% for VHT (reporting dates differ).
Updated Nov 19, 2026
VHT vs LOGSX side by side
| VHT | LOGSX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | Vanguard | Oak Associates |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.09% | 1.04% |
| Annual cost per $10k | $9 | $104 |
| 10-yr cost on $10k (prospectus) | $115 | $1,271 |
| Max front load | None | — |
| 12b-1 fee | 0% | — |
| 1-yr return | +2.7% | +19.6% |
| 5-yr return (annualized) | +7.2% | +8.1% |
| 10-yr return (annualized) | +8.8% | +7.3% |
| Best quarter | +16.5% | +13.4% |
| Worst quarter | −13.1% | −13.1% |
| Net assets (fund) | $19.0B | $56.1M |
| Number of holdings | 407 | 28 |
| Portfolio turnover | 4% | 24% |
| Returns as of | Dec 31, 2024 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | VHT | LOGSX | Difference |
|---|---|---|---|
| 2024 | +2.7% | +0.2% | +2.5% |
| 2023 | +2.5% | +1.2% | +1.3% |
| 2022 | −5.5% | +3.7% | −9.2% |
| 2021 | +20.5% | +17.5% | +3.0% |
| 2020 | +18.2% | +6.0% | +12.2% |
| 2019 | +22.0% | +19.0% | +3.0% |
| 2018 | +5.6% | −4.0% | +9.5% |
| 2017 | +23.3% | +13.4% | +9.9% |
| 2016 | −3.3% | −0.4% | −3.0% |
Source: Fund prospectus bar charts
Holdings overlap
13 of VHT's top 25 holdings also appear in LOGSX's top 25.
| Holding | VHT | LOGSX |
|---|---|---|
| Eli Lilly & Co | 14.04% | 1.99% |
| Johnson & Johnson | 8.47% | 3.77% |
| Merck & Co Inc | 4.66% | 3.16% |
| Amgen Inc | 2.87% | 4.86% |
| Gilead Sciences Inc | 2.64% | 3.50% |
| Intuitive Surgical Inc | 2.38% | 2.99% |
| Bristol-Myers Squibb Co | 1.84% | 4.02% |
| Vertex Pharmaceuticals Inc | 1.80% | 3.26% |
| Medtronic PLC | 1.50% | 3.01% |
| McKesson Corp | 1.45% | 4.53% |
| Cigna Group/The | 1.17% | 3.46% |
| Regeneron Pharmaceuticals Inc | 1.00% | 4.43% |
| Cencora Inc | 0.79% | 4.46% |
Source: SEC Form N-PORT
VHT top 10
- Eli Lilly & Co — 14.04%
- Johnson & Johnson — 8.47%
- AbbVie Inc — 6.09%
- UnitedHealth Group Inc — 5.45%
- Merck & Co Inc — 4.66%
- Thermo Fisher Scientific Inc — 2.93%
- Amgen Inc — 2.87%
- Gilead Sciences Inc — 2.64%
- Intuitive Surgical Inc — 2.38%
- Pfizer Inc — 2.35%
LOGSX top 10
- N/a — 6.91%
- Cardinal Health Inc — 5.86%
- Jazz Pharmaceuticals Plc — 5.77%
- United Therapeutics Corp — 5.11%
- Exelixis Inc — 4.95%
- Amgen Inc — 4.86%
- Lantheus Holdings Inc — 4.68%
- Novartis Ag — 4.67%
- Mckesson Corp — 4.53%
- Cencora Inc — 4.46%
FAQ
What is the difference between VHT and LOGSX?
Which is cheaper, VHT or LOGSX?
Should I own both VHT and LOGSX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.